The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy

2007 ◽  
Vol 24 (2) ◽  
pp. 187-194 ◽  
Author(s):  
C. J. Currie ◽  
C. D. Poole ◽  
A. Woehl ◽  
C. Ll. Morgan ◽  
S. Cawley ◽  
...  
2015 ◽  
Vol 32 (9) ◽  
pp. 1119-1120 ◽  
Author(s):  
N. Holman ◽  
B. Young ◽  
R. Gadsby

Diabetes ◽  
2019 ◽  
Vol 68 (11) ◽  
pp. 2143-2154 ◽  
Author(s):  
Corinne G. Jolivalt ◽  
Alexandra Marquez ◽  
David Quach ◽  
Michelle C. Navarro Diaz ◽  
Carlos Anaya ◽  
...  

2015 ◽  
Vol 20 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Matthew S. Yorek ◽  
Alexander Obrosov ◽  
Hanna Shevalye ◽  
Amey Holmes ◽  
Matthew M. Harper ◽  
...  

Author(s):  
Faisal Suliman Algaows ◽  
Fatema Abdullah Althkerallah ◽  
Norah Abdulmohsen Alsuwailem ◽  
Amnah Abdulnasser Mawlan Ahmed ◽  
Razan Fahad Alwagdani ◽  
...  

Diabetic neuropathy is a long-term consequence of diabetes that can cause significant morbidity and a decline in quality of life in many individuals. Low vitamin D levels, in addition to causing rickets in infants and chondrosteoma in adults, may have a role in the development of DM and its underlying disorders, according to a growing body of evidence. Vitamin D deficiency has been linked to type 1 or type 2 diabetes, as well as the microvascular and macrovascular problems that come with it. Vitamin D insufficiency has been linked to diabetic peripheral neuropathy (DPN) as an independent risk factor. Vitamin D, both topical and oral, has been shown to considerably improve DPN symptoms and pain.


2020 ◽  
Author(s):  
Maryam Ferdousi ◽  
Alise Kalteniece ◽  
Shazli Azmi ◽  
Ioannis N Petropoulos ◽  
Georgios Ponirakis ◽  
...  

<b>Purpose: </b>To assess the diagnostic utility of corneal confocal microscopy (CCM) for diabetic peripheral neuropathy (DPN) and the risk factors for corneal nerve loss. <p><b>Methods: </b>490 participants including 72 healthy controls, 149 with type 1 diabetes and 269 with type 2 diabetes underwent detailed assessment of peripheral neuropathy and CCM in relation to risk factors.</p> <p><b>Results: </b>Corneal nerve fibre density (CNFD) (P<0.0001, P<0.0001), branch density (CNBD) (P<0.0001, P<0.0001) and length (CNFL) (P<0.0001, P=0.02) were significantly lower in patients with type 1 and type 2 diabetes, compared to controls. CNFD (P<0.0001), CNBD (P<0.0001) and CNFL (P<0.0001) were lower in type 1 diabetes compared to type 2 diabetes. Receiver operating characteristics (ROC) curve analysis for the diagnosis of DPN demonstrated a good area under the curve (AUC) for CNFD=0.81, CNBD=0.74 and CNFL=0.73. Multivariable regression analysis showed a significant association between reduced corneal nerve fibre length with age (β=-0.27, P=0.007), HbA1c (β=-1.1, P=0.01) and weight (β=-0.14, P=0.03) in patients with type 2 diabetes and with duration of diabetes (β=-0.13, P=0.02), LDL cholesterol (β=1.8, P=0.04), and triglycerides (β=-2.87, P=0.009) in patients with type 1 diabetes. </p> <b>Conclusion: </b>CCM identifies more severe corneal nerve loss in patients with type 1 compared to type 2 diabetes and shows good diagnostic accuracy for DPN. Furthermore, the risk factors for a reduction in corneal nerve fibre length differ between type 1 and type 2 diabetes.


Sign in / Sign up

Export Citation Format

Share Document